Transcutaneous Spinal Cord Stimulation for Upper Extremity Function

Inclusion Criteria: SCI cohort: * individuals aged 18 to 75 years of age who have suffered a spinal cord injury * cervical level injury (C3 to C8) * at least 1-year post-injury * for individuals taking medications for spasmolysis or muscle relaxation (e.g. oral baclofen, tizanidine, dantrolene, vigabatrin, gabapentin, or benzodiazepine), dose and regimen must be stable for at least 4 weeks prior to screening Stroke cohort: * individuals aged 18-75 years of age who have suffered any type of stroke resulting in upper extremity motor dysfunction with partially preserved motor function * ≥ 6 months post-stroke * At least 4 months since last BoNT injection for treatment of spasticity or any other condition or ≤ 2 months after study completion * for individuals taking medications for spasmolysis or muscle relaxation (e.g. oral baclofen, tizanidine, dantrolene, vigabatrin, gabapentin, or benzodiazepine), dose and regimen must be stable for at least 4 weeks prior to screening Exclusion Criteria: * pregnant women * aphasia or dysphasia * spasticity grade Modified Ashworth Scale ≥ 3 Transcranial magnetic stimulation-specific exclusion criteria (both cohorts) * participants with active or inactive implants including cardiac pacemakers, implantable defibrillators, ocular implants, deep brain stimulators, vagus nerve stimulator, and implanted medication pumps * participants with conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head * participants wit…